News & Updates
Filter by Specialty:
RA patient’s perspective must be respected in treatment decisions, says study
Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.
RA patient’s perspective must be respected in treatment decisions, says study
07 Jul 2022
Distinct plasma vs gut microbiome seen in SLE patients, healthy individuals
A distinct community and greater heterogeneity have been observed in the plasma microbiome compared to the gut in both patients with systemic lupus erythematosus (SLE) and healthy individuals, reports a recent study. This suggests that the predominant circulating microbiome may originate from sites other than the gastrointestinal tract.
Distinct plasma vs gut microbiome seen in SLE patients, healthy individuals
03 Jul 2022
Gout patients endorse reasons for not taking allopurinol
Patients with gout who refuse to take allopurinol for their condition do so because of their desire to lead a normal life and to test whether they could reduce the dose without experiencing any symptoms, a recent study has found.
Gout patients endorse reasons for not taking allopurinol
02 Jul 2022
How safe for the heart is hydroxychloroquine use in RA patients?
The risks of sudden cardiac arrest or ventricular arrythmia (SCA/VA) and major adverse cardiovascular event (MACE) are comparable between methotrexate (MTX) and hydroxychloroquine (HCQ) in older patients with rheumatoid arthritis (RA), reports a study.
How safe for the heart is hydroxychloroquine use in RA patients?
01 Jul 2022
Do bDMARDs prevent osteoporotic fractures in RA patients?
Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.
Do bDMARDs prevent osteoporotic fractures in RA patients?
01 Jul 2022
Baricitinib delays, lowers frequency of flares in JIA
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
Change in serum marker levels tied to outcomes of RA-related interstitial lung disease
In rheumatoid arthritis-related interstitial lung disease (RA-ILD), change over time in the levels of serum proteins, such as matrix metallopeptidase 13 (MMP13) and C-X-C motif ligand chemokine 11 (CXCL11), predict clinical outcomes, a recent study has found. The same is true for baseline clinical factors such as patient age and rheumatoid factor.